NEW YORK (GenomeWeb) – Cantor Fitzgerald yesterday initiated coverage of molecular diagnostic firms Rosetta Genomics and Veracyte with ratings of speculative buy and buy, respectively.

Cantor analyst Brian Brokmeier set a $3 to $5 fair value on Rosetta's shares, citing the firm's shift over the last year from a "niche player in the cancer of unknown primary (CUP) market into a molecular diagnostics lab with a portfolio of tests targeting the oncology market."

Rosetta's shares were trading up more than 11 percent at $1.38 during early morning trading on the Nasdaq Friday.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.